Propanc Biopharma Don Raise $100M Crypto Treasury for PRP Trials
Propanc Biopharma don agree with Hexstone Capital to set up crypto treasury wey fit reach $100 million. The private placement wey dem arrange as convertible preferred stock, go start with $1 million initial investment and e go fit add another $99 million for 12 months. This waka go diversify Propanc balance sheet and e go help fund their proenzyme-based PRP cancer therapy wey dey target metastatic solid tumors and dem plan to run Phase I trials for second half of 2026.
Even though Propanc never talk exact crypto allocation, market people dey expect say Bitcoin (BTC), Ether (ETH), and Solana (SOL) go dey main, because e match Hexstone portfolio. To create digital asset treasury show say many biotech companies dey use crypto market take finance their work. But this movement get wahala of volatility, regulation and custody challenges.
Propanc shares wey dey Nasdaq fall 12% because of this news, wey show say investors dey cautious about company crypto treasuries. Traders suppose watch Propanc crypto allocation policy well well plus PRP trial milestones. These things fit be catalyst for both biotech and digital asset markets, dem go affect crypto treasury demand and token prices.
Neutral
Even though Propanc’s $100M crypto treasury plan fit make institutional demand for beta tokens like BTC, ETH, and SOL increase, the size small compared to global markets and e get regulatory and custody wahala. Short-term price effect no go too much; long-term effect go depend on actual allocations, PRP trial success and wider corporate adoption. Traders suppose dey watch allocation disclosure and trial updates as possible catalysts.